Descovy

Saudi Arabia · access guide

How to access Descovy for HIV-1 treatment and PrEP from Saudi Arabia: 2026 pathway via KFSHRC, KAMC NGHA, and the Saudi National HIV/AIDS Programme

By Reserve Meds clinical & regulatory team. Last reviewed 2026-05-20.

Saudi Arabia operates a coordinated National HIV/AIDS Programme through the Ministry of Health, with HIV diagnosis, treatment initiation, and ongoing care delivered through a small number of designated infectious diseases services and academic medical centres. King Faisal Specialist Hospital and Research Centre (KFSHRC) Riyadh and Jeddah, King Abdulaziz Medical City (KAMC) National Guard Health Affairs in Riyadh and Jeddah, King Saud University Medical City, Prince Sultan Military Medical City, King Fahad Medical City, and a small number of MoH-designated infectious diseases clinics handle the prescribing conversation. The Saudi MoH coordinates antiretroviral supply through NUPCO for MoH and military health facilities. Descovy (emtricitabine 200 mg + tenofovir alafenamide 25 mg; FTC/TAF) is the Gilead 2-NRTI backbone, registered with the Saudi Food and Drug Authority for HIV-1 treatment, and used in combination with a third antiretroviral agent (INSTI, NNRTI, or boosted PI). Descovy also carries an FDA indication for HIV PrEP in selected adult populations; PrEP recognition and prescription patterns in Saudi public health are more variable and specialist-driven.

For a Saudi-resident patient living with HIV-1 or seeking PrEP where the indication applies, the operational question is which prescribing centre handles the case, how the national programme funding works, how the confidentiality framework is operationalised, and how the quarterly monitoring and monthly refill cycle settles into life.

This page explains how the pathway works in 2026 for a Saudi-resident patient on either indication. It is concierge documentation written for patients who are already in conversation with an infectious diseases specialist and want the operational reality laid out plainly, with the confidentiality discipline that HIV care requires.

Why Descovy, and why now

Descovy is the fixed-dose combination of emtricitabine (FTC) and tenofovir alafenamide (TAF) in a single once-daily oral tablet from Gilead. The molecule pair is a 2-NRTI backbone for HIV-1 treatment. Descovy is the successor to Truvada (FTC/TDF), with the TAF prodrug delivering equivalent intracellular antiviral concentrations at approximately 90 percent lower plasma tenofovir exposure. The clinical consequence is reduced renal proximal tubular toxicity and reduced bone mineral density loss versus TDF. Descovy is the preferred 2-NRTI backbone for patients with reduced eGFR, osteoporosis or osteopenia, or other renal/bone risk factors.

The FDA approved Descovy for HIV-1 treatment in April 2016 and for PrEP in October 2019, with the PrEP indication restricted to populations studied in the DISCOVER trial (cisgender men who have sex with men and transgender women); cisgender women and others at risk from receptive vaginal sex should use Truvada for PrEP, not Descovy. The EMA approved Descovy for treatment in April 2016. The pivotal Phase 3 treatment data (GS-US-292-0104 and -0111) demonstrated non-inferiority of FTC/TAF-based regimens versus FTC/TDF-based regimens with significantly less renal and bone toxicity. The pivotal PrEP data (DISCOVER) demonstrated non-inferiority for HIV prevention in the studied population.

For a Saudi patient starting first-line antiretroviral therapy in 2026, Descovy is the standard 2-NRTI backbone, typically combined as Biktarvy (bictegravir/FTC/TAF as a single-tablet regimen) or as Descovy plus dolutegravir as separate tablets. The decision rests with the prescribing infectious diseases specialist based on resistance genotype, comorbidities, drug interactions, and patient preference.

What Descovy is, in plain language

Descovy is a single oral tablet taken once daily, with or without food, at approximately the same time each day. Each tablet contains FTC 200 mg and TAF 25 mg. Storage is room temperature; no refrigeration. There is no infusion, no inpatient stay, no specialty-centre administration requirement.

For HIV TREATMENT, Descovy is the 2-NRTI backbone and must be combined with a third agent (INSTI such as dolutegravir or bictegravir, NNRTI such as rilpivirine or doravirine, or boosted PI such as darunavir/cobicistat). The most common modern combination is Biktarvy, which co-formulates Descovy with bictegravir in one tablet.

For PrEP, Descovy is taken alone, one tablet daily, indefinite duration as long as ongoing HIV exposure risk continues.

Eligibility at a Saudi infectious diseases clinic

For HIV TREATMENT:

1. Confirmed HIV-1 diagnosis by serology and confirmatory testing per Saudi national algorithm. Baseline HIV-1 viral load and CD4 count. 2. HIV-1 resistance genotype before initiating antiretroviral therapy. 3. Hepatitis B serology (HBsAg, anti-HBs, anti-HBc). HBV-coinfected patients receive effective HBV treatment from the Descovy components; discontinuation carries a boxed warning for severe acute HBV flare and requires hepatology coordination. 4. Renal function (serum creatinine, eGFR, urinalysis). Descovy is appropriate where eGFR is at or above 30 mL/min; not recommended below 30 or on chronic haemodialysis. 5. Hepatic function; no dose adjustment for mild or moderate hepatic impairment. 6. Pregnancy and lactation screen for women of reproductive potential. 7. Drug interaction screen, particularly for P-glycoprotein inducers (rifampin, rifabutin, carbamazepine, phenytoin, St John's wort) which substantially reduce TAF exposure. 8. Lipid panel given the modest LDL and triglyceride increase versus Truvada. 9. Mental health and substance use screen. 10. STI screen at baseline.

For PrEP (in addition to relevant items above):

1. Confirmed HIV-NEGATIVE status using a 4th-generation Ag/Ab combination assay AND HIV-1 RNA PCR at baseline. This is the single most important pre-PrEP gate; PrEP in undiagnosed HIV causes M184V resistance. 2. No symptoms suggestive of acute HIV in the preceding 28 days. 3. HBV serology; vaccination if non-immune. 4. STI screening; repeat every 3 months on PrEP. 5. Confirmation that the PrEP-indicated exposure profile applies. 6. Counselling on daily adherence, residual STI risk, and risk reassessment.

A Saudi patient should arrive at the infectious diseases conversation with the most recent diagnostic workup if known and the documentation pack assembled with the patient's explicit authorisation. Reserve Meds handles this assembly under the same confidentiality discipline as the prescribing centre.

The Saudi prescribing and dispense picture, plainly

Descovy is registered with the SFDA for HIV-1 treatment. The functional supply chain is:

1. **Prescribing infectious diseases specialist**: a Saudi-board-certified infectious diseases consultant with HIV clinical experience. Major Saudi prescribing centres include KFSHRC Riyadh and Jeddah infectious diseases (the deepest HIV-care expertise in the Kingdom), KAMC NGHA Riyadh and Jeddah infectious diseases, King Saud University Medical City infectious diseases, Prince Sultan Military Medical City infectious diseases, King Fahad Medical City infectious diseases, King Khalid University Hospital infectious diseases, KFSH Dammam, IMC Jeddah infectious diseases, and the Dr Sulaiman Al Habib network infectious diseases services for private-channel patients. The Saudi MoH coordinates the national HIV programme across designated centres. 2. **Diagnostic workup**: HIV-1 viral load, CD4, resistance genotype, HBV and HCV serology, baseline renal and hepatic panels, STI screen, lipid panel are performed at the prescribing centre's laboratory or a reference lab. All testing is confidential under the centre's HIV care confidentiality framework. 3. **Insurance and funding**: for Saudi nationals, HIV antiretroviral medication is funded through the national HIV programme via MoH or military health channels with minimal or zero out-of-pocket cost for the medication itself. CCHI commercial covers vary; some private insurers cover HIV care explicitly, others handle it through a separate pathway to preserve confidentiality. NUPCO handles the supply chain for MoH and military health facilities. 4. **Pharmacy dispense**: the prescribing centre's outpatient pharmacy. Community pharmacy dispense for HIV antiretrovirals is uncommon in Saudi Arabia because of the centralised programmatic structure and the confidentiality framework. 5. **Refill cycle**: typically monthly or every 2 months, coordinated with the quarterly clinical review at the centre. Continued dispensing requires clinic attendance, viral load suppression documentation, and renal function monitoring.

For PrEP in Saudi Arabia: PrEP prescribing is concentrated at the major infectious diseases centres listed above with specific clinicians familiar with the PrEP indication. PrEP is not promoted in primary care and is not widely advertised. Serodifferent-couple PrEP is the clearest indication and the most established pathway. Other PrEP indications are clinically recognised by WHO and CDC and are discussed with the prescribing specialist on a patient-specific basis. Public-sector PrEP funding is variable; the prescribing centre's case-management team coordinates the conversation.

The 2026 pathway, step by step

Week 0 to 2: Reserve Meds builds the documentation pack with the patient's explicit authorisation. All documentation is handled with the confidentiality discipline that HIV care requires.

Week 2 to 4: First infectious diseases consultation. Baseline workup confirmed or rerun; regimen choice (TREATMENT) or eligibility confirmation (PrEP) finalised.

Week 4 to 5: First dispense at the prescribing centre's outpatient pharmacy.

Week 4 (TREATMENT): early-treatment monitoring visit; viral load and renal function rechecked.

Month 3: clinical review. TREATMENT: viral load, CD4, renal function, adherence, side effects. PrEP: HIV testing, STI screen, renal function, adherence and risk reassessment.

Month 6: clinical review. TREATMENT: viral load, CD4, renal function, lipid panel. PrEP: HIV testing, STI screen, renal function.

Ongoing: TREATMENT moves to 3-monthly to 6-monthly reviews depending on stability. PrEP continues with 3-monthly visits.

Cost expectation in SAR

US Descovy list price (2026) is approximately USD 2,150 to USD 2,400 per 30-day supply, annual approximately USD 25,800 to USD 28,800 at list price. International Descovy supply through Gilead's Saudi distributor channel often lands at a lower price point; NUPCO procurement for MoH and military facilities further reduces the cost to the public system.

At indicative 2026 cross rates, a 30-day Descovy supply at USD 2,200 is approximately SAR 8,250, and the annual cost at USD 26,500 is approximately SAR 99,375. For Saudi nationals funded through the national HIV programme, out-of-pocket cost for the medication itself is typically minimal or zero. The annual cash-pay band applies only where the patient is self-paying through the private channel without national programme support.

For PrEP, public-sector funding in Saudi Arabia is variable and clinician-dependent. The prescribing centre's case-management team coordinates the funding conversation; private-channel PrEP cost typically tracks the annual cash-pay band above.

Monitoring on therapy

For HIV TREATMENT:

- HIV-1 viral load at 4 weeks, then 3-monthly until durably suppressed, then 6-monthly. - CD4 at baseline, 6-monthly until durably suppressed, then annually. - Renal function (serum creatinine, eGFR, urinalysis) at baseline, 3 months, 6 months, then 6 to 12 monthly. Regimen change if eGFR drops below 30 or if proximal tubulopathy develops. - Hepatitis B at baseline; HBV DNA monitoring in HBV-coinfected patients. - Lipid panel at baseline, 6 months, then annually. - Drug interaction review at each visit. - Mental health follow-up at clinically appropriate intervals.

For PrEP:

- HIV testing every 3 months (4th-generation Ag/Ab assay; PCR if clinical concern). - STI screening every 3 months. - Renal function at baseline, 3 months, then 6-monthly. - HBV status at baseline; vaccination if non-immune. - Adherence and risk reassessment at each 3-monthly visit.

Religious, ethical, and family-logistics framing

Descovy is an oral small molecule with no animal-source material. Halal and kosher acceptability are not in question. The classical Islamic jurisprudential framework for treatment of serious illness endorses antiretroviral therapy. PrEP framing in Islamic ethical traditions is more nuanced and is a patient-specific clinical conversation.

HIV care in Saudi Arabia operates under a strict confidentiality framework given the significant social and legal sensitivity around HIV. The major prescribing centres operationalise this with separate clinic pathways, dedicated case management, and confidential medical records handling. Reserve Meds operates with the same discipline; we do not disclose HIV-related case context to family members, employers, insurers, or any party other than the patient and the patient's named treating clinicians, except where the patient has explicitly authorised that disclosure.

Modern HIV treatment in 2026 renders HIV a chronic, manageable condition with normal life expectancy. People living with HIV on suppressive treatment with undetectable viral load do not sexually transmit HIV to partners (U=U). The clinical conversation centres on starting effective treatment, achieving suppression, and supporting patient quality of life and dignity.

For PrEP, the clinical conversation centres on HIV prevention as a public-health intervention. Serodifferent partnerships are a clinically standard and dignified PrEP indication and the clearest pathway for PrEP access in Saudi Arabia. Other indications are recognised clinically and discussed patient by patient.

Mental health support is part of comprehensive HIV care. Several Saudi infectious diseases services have integrated or partnered mental health pathways.

When Descovy is not the right call

For HIV TREATMENT, Descovy is not the right answer for patients with eGFR below 30, documented M184V/I or K65R resistance, or those on strong P-glycoprotein inducers where alternative regimens are preferred. For PrEP, Descovy is not appropriate for cisgender women and others at risk from receptive vaginal sex (use Truvada), for anyone with undiagnosed HIV (test first), for anyone with eGFR below 30, or for anyone unable to commit to daily dosing and quarterly monitoring.

Alternatives include Biktarvy (single-tablet, INSTI-based first-line for treatment-naive adults), Truvada-based regimens, Dovato (dolutegravir/lamivudine), long-acting injectable Cabenuva for stable suppressed patients, and for PrEP populations not indicated for Descovy, Truvada is the broader-label first-line option.

Reserve Meds does not push a default. If the conversation with the treating infectious diseases specialist points toward Biktarvy, Truvada, Dovato, Cabenuva, or another agent, the operational pathway shifts accordingly.

What Reserve Meds does on this case

We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On a Saudi Descovy case we build the documentation pack with the patient's explicit authorisation under the confidentiality discipline that HIV care requires, submit first-review requests to the chosen prescribing centre, coordinate the national programme or CCHI funding conversation alongside the clinical workup, set up the first dispense at the prescribing centre's outpatient pharmacy, organise the early-treatment or early-PrEP monitoring schedule, and stay with the case through the first year with handoff to the local infectious diseases specialist for ongoing care. Clinical decisions remain with your treating infectious diseases specialist.

Reserve Meds's role

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

reservemeds.com · hello@reservemeds.com